JP2019534867A - カンナビノイド受容体結合リガンドを含む組成物 - Google Patents

カンナビノイド受容体結合リガンドを含む組成物 Download PDF

Info

Publication number
JP2019534867A
JP2019534867A JP2019516407A JP2019516407A JP2019534867A JP 2019534867 A JP2019534867 A JP 2019534867A JP 2019516407 A JP2019516407 A JP 2019516407A JP 2019516407 A JP2019516407 A JP 2019516407A JP 2019534867 A JP2019534867 A JP 2019534867A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
thc
composition according
receptor binding
cannabinoid receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019516407A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019534867A5 (enExample
Inventor
ベルンハルト グンター，
ベルンハルト グンター，
フランク ルッシャー，
フランク ルッシャー，
ソンニャ クレッサー，
ソンニャ クレッサー，
フィリップ スティーヴェン
フィリップ スティーヴェン
Original Assignee
ノバリック ゲーエムベーハー
ノバリック ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバリック ゲーエムベーハー, ノバリック ゲーエムベーハー filed Critical ノバリック ゲーエムベーハー
Publication of JP2019534867A publication Critical patent/JP2019534867A/ja
Publication of JP2019534867A5 publication Critical patent/JP2019534867A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2019516407A 2016-09-28 2017-09-27 カンナビノイド受容体結合リガンドを含む組成物 Pending JP2019534867A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP16191194.6 2016-09-28
EP16191194 2016-09-28
EP17168172.9 2017-04-26
EP17168172 2017-04-26
PCT/EP2017/074545 WO2018060282A1 (en) 2016-09-28 2017-09-27 Compositions comprising a cannabinoid receptor binding ligand

Publications (2)

Publication Number Publication Date
JP2019534867A true JP2019534867A (ja) 2019-12-05
JP2019534867A5 JP2019534867A5 (enExample) 2020-04-09

Family

ID=59966776

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019516407A Pending JP2019534867A (ja) 2016-09-28 2017-09-27 カンナビノイド受容体結合リガンドを含む組成物

Country Status (10)

Country Link
US (1) US20190343793A1 (enExample)
EP (2) EP3698785A1 (enExample)
JP (1) JP2019534867A (enExample)
KR (1) KR20190060787A (enExample)
CN (1) CN109803650A (enExample)
AU (1) AU2017333420A1 (enExample)
BR (1) BR112019006194A2 (enExample)
CA (1) CA3036313A1 (enExample)
MX (1) MX2019003544A (enExample)
WO (1) WO2018060282A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021073541A (ja) * 2016-12-27 2021-05-13 フェイスブック・テクノロジーズ・リミテッド・ライアビリティ・カンパニーＦａｃｅｂｏｏｋ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｌｌｃ 触覚デバイスの大規模集積化
JP2023543925A (ja) * 2020-10-05 2023-10-18 マックス バイオロジー カンパニー リミテッド カンナビノイド含有組成物及び疾患の処置及び予防のための使用
JP2023546649A (ja) * 2020-09-24 2023-11-07 ニコベンチャーズ トレーディング リミテッド 製剤

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101656121B1 (ko) 2010-03-17 2016-09-08 노바리크 게엠베하 안압 증가를 치료하기 위한 약학 조성물
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
DK2895144T3 (en) 2012-09-12 2017-03-06 Novaliq Gmbh SEMIFLUORED ALKAN COMPOSITIONS
EP3100722B1 (en) 2012-09-12 2024-03-20 Novaliq GmbH Semifluorinated alkanes for use in solubilizing meibum
US10273298B2 (en) 2013-07-23 2019-04-30 Novaliq Gmbh Stabilized antibody compositions
US11154513B2 (en) 2015-09-30 2021-10-26 Novaliq Gmbh Semifluorinated compounds
US20170087100A1 (en) 2015-09-30 2017-03-30 Novaliq Gmbh Semifluorinated compounds and their compositions
AU2017260444B2 (en) 2016-05-03 2019-05-09 Pneuma Respiratory, Inc. Droplet delivery device for delivery of fluids to the pulmonary system and methods of use
JP2019520357A (ja) 2016-06-23 2019-07-18 ノバリック ゲーエムベーハー 局所投与方法
JP7012075B2 (ja) 2016-09-22 2022-01-27 ノバリック ゲーエムベーハー 眼瞼炎の治療に使用するための医薬組成物
JP6869336B2 (ja) 2016-09-23 2021-05-12 ノバリック ゲーエムベーハー シクロスポリンを含む眼科用組成物
ES2957559T3 (es) 2017-04-21 2024-01-22 Dermaliq Therapeutics Inc Composiciones de yodo
WO2018206656A1 (en) 2017-05-12 2018-11-15 Novaliq Gmbh Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions
KR20200059272A (ko) 2017-09-27 2020-05-28 노바리크 게엠베하 안구 질환의 치료에서의 사용을 위한 라타노프로스트를 포함하는 안과적 조성물
CN111526914A (zh) 2017-10-04 2020-08-11 精呼吸股份有限公司 电子呼吸致动式直线型液滴输送装置及其使用方法
US11896559B2 (en) 2017-10-04 2024-02-13 Novaliq Gmbh Opthalmic compositions comprising F6H8
EP3706843B1 (en) 2017-11-08 2024-06-26 Pneuma Respiratory, Inc. Electronic breath actuated in-line droplet delivery device with small volume ampoule
JP7353292B2 (ja) 2018-03-02 2023-09-29 ノバリック ゲーエムベーハー ネビボロールを含む医薬組成物
US12226422B2 (en) 2018-04-27 2025-02-18 Novaliq Gmbh Ophthalmic compositions comprising tafluprost for the treatment of glaucoma
CA3112031A1 (en) 2018-10-12 2020-04-16 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
CA3128224A1 (en) * 2019-02-01 2020-08-06 Aerie Pharmaceuticals, Inc. Compounds, compositions and methods for treatment of myopia
US12397039B2 (en) 2019-02-13 2025-08-26 Novaliq Gmbh Compositions and methods for the treatment of ocular neovascularization
US12419933B2 (en) 2019-09-06 2025-09-23 Novaliq Gmbh Ophthalmic composition for the treatment of uveitis
US11191751B1 (en) * 2020-10-08 2021-12-07 Ads Therapeutics Llc Topical ophthalmological atropine free base compositions
KR20230142548A (ko) 2021-02-03 2023-10-11 에이디에스 테라퓨틱스 엘엘씨 국소 안과용 조성물
EP4359046B1 (en) 2021-06-22 2025-08-27 Pneuma Respiratory, Inc. Droplet delivery device with push ejection
US20250228876A1 (en) * 2021-10-13 2025-07-17 Pneuma Respiratory, Inc. Compositions for delivery of cannabinoids
CN119768202A (zh) 2022-07-18 2025-04-04 精呼吸股份有限公司 小步长高分辨率气溶胶生成系统及方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000511157A (ja) * 1995-09-29 2000-08-29 マイネルト，ハッソ セミフルオロアルカン及びその使用
JP2013513586A (ja) * 2009-12-14 2013-04-22 ノバリック ゲーエムベーハー ドライアイ症候群の治療のための医薬組成物
JP2013540140A (ja) * 2010-10-20 2013-10-31 ノバリック ゲーエムベーハー 有効成分の送達のための液体医薬組成物
WO2015074137A1 (en) * 2013-11-20 2015-05-28 Mary Lynch Compositions and methods for treatment of ocular inflammation and pain
WO2016109531A1 (en) * 2014-12-30 2016-07-07 Axim Biotechnologies, Inc. Ophthalmic solutions for glaucoma and conjunctivitis treatment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101516333A (zh) 2006-08-04 2009-08-26 英西斯治疗学股份有限公司 水性屈大麻酚制剂
US8222292B2 (en) 2007-08-06 2012-07-17 Insys Therapeutics, Inc. Liquid cannabinoid formulations
HUE032158T2 (en) 2008-10-31 2017-09-28 Univ Mississippi Process for the preparation of delta9-THC amino acid esters
AT509000B1 (de) * 2009-10-23 2012-12-15 Rausch Peter Wasserlösliche zubereitungen von cannabinoiden und cannabispräparaten und deren anwendungen
US8758826B2 (en) 2011-07-05 2014-06-24 Wet Inc. Cannabinoid receptor binding agents, compositions, and methods
EP3100722B1 (en) * 2012-09-12 2024-03-20 Novaliq GmbH Semifluorinated alkanes for use in solubilizing meibum
DK2895144T3 (en) * 2012-09-12 2017-03-06 Novaliq Gmbh SEMIFLUORED ALKAN COMPOSITIONS
WO2015053829A1 (en) 2013-10-09 2015-04-16 Johnson Living Trust Dated October 26, 2001, Leonidas A. Johnson, Trustee Methods and compositions for treating and preventing signs or symptoms of eye disease

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000511157A (ja) * 1995-09-29 2000-08-29 マイネルト，ハッソ セミフルオロアルカン及びその使用
JP2013513586A (ja) * 2009-12-14 2013-04-22 ノバリック ゲーエムベーハー ドライアイ症候群の治療のための医薬組成物
JP2013540140A (ja) * 2010-10-20 2013-10-31 ノバリック ゲーエムベーハー 有効成分の送達のための液体医薬組成物
WO2015074137A1 (en) * 2013-11-20 2015-05-28 Mary Lynch Compositions and methods for treatment of ocular inflammation and pain
WO2016109531A1 (en) * 2014-12-30 2016-07-07 Axim Biotechnologies, Inc. Ophthalmic solutions for glaucoma and conjunctivitis treatment

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AM J DRUG DELIV, vol. 2, no. 4, JPN6021023811, 2004, pages 229 - 240, ISSN: 0004827481 *
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, vol. 88, JPN6021023813, 2014, pages 123 - 128, ISSN: 0004827482 *
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 57, JPN6021023814, 2016, pages 417, ISSN: 0004827483 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021073541A (ja) * 2016-12-27 2021-05-13 フェイスブック・テクノロジーズ・リミテッド・ライアビリティ・カンパニーＦａｃｅｂｏｏｋ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｌｌｃ 触覚デバイスの大規模集積化
JP2023546649A (ja) * 2020-09-24 2023-11-07 ニコベンチャーズ トレーディング リミテッド 製剤
JP2023543925A (ja) * 2020-10-05 2023-10-18 マックス バイオロジー カンパニー リミテッド カンナビノイド含有組成物及び疾患の処置及び予防のための使用

Also Published As

Publication number Publication date
KR20190060787A (ko) 2019-06-03
EP3698785A1 (en) 2020-08-26
AU2017333420A1 (en) 2019-04-04
BR112019006194A2 (pt) 2019-06-18
EP3518921A1 (en) 2019-08-07
CA3036313A1 (en) 2018-04-05
WO2018060282A1 (en) 2018-04-05
US20190343793A1 (en) 2019-11-14
CN109803650A (zh) 2019-05-24
EP3518921B1 (en) 2021-08-11
MX2019003544A (es) 2019-09-19

Similar Documents

Publication Publication Date Title
EP3518921B1 (en) Compositions comprising a cannabinoid receptor binding ligand
JP6397472B2 (ja) ドライアイ症候群の治療のための医薬組成物
US9937225B2 (en) Topical formulations and uses thereof
US20200009137A1 (en) Topical formulations and uses thereof
WO2017152129A2 (en) Treatment of glaucoma and/or retinal diseases and formulations useful therefore
HK40036791A (en) Compositions comprising a cannabinoid receptor binding ligand
HK40008248A (en) Compositions comprising a cannabinoid receptor binding ligand

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200226

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200925

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210614

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210622

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210915

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211222

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220719